The API of GlaxoSmithKline's ($GSK) HIV therapy Tivicay (dolutegravir) will be made in China by Shanghai-based Desano Pharmaceuticals under a deal with the British drugmaker's ViiV Healthcare arm, according to a press release. The drug will be available in China and other developing countries under various access initiatives and sees GSK make a mark in the country that follows from its commitment to widen its reach following an RMB3 billion ($484 million) fine last year for bribing Chinese doctors to buy its drugs. The access product would be sold at a "competitive" price discount, the release said. Release | More from FiercePharmaManufacturing